Not medical advice. A record of published research and our assessments of it. The limits

The Use of Liraglutide in Brain Death

Randomized Clinical Trial to Evaluate the Use of Liraglutide in Individuals With Brain Death and Anti-inflammatory and Anti-apoptotic Effects on Organs to be Transplanted
NCT03672812 on ClinicalTrials.gov

Status: CompletedResults none
Why it is watched: non-weight indication: inflammation
Who it enrolls: age 18 Years to no upper limit; no BMI minimum stated; conditions: Brain Death
Interventions: Liraglutide
Conditions: Brain Death
Phase and size: Phase 3 · 50 participants
Dates: Start 2018-09-01
Primary completion 2019-12-10
Sponsor: Hospital de Clinicas de Porto Alegre (Other)
Last checked: Sep 13, 2026

01Endpoints

What the trial will measure

change inflammationfrom 6 hours to 24 hours

02Eligibility

Who can take part

Inclusion Criteria: * individuals deceased more than 18 years after the end of the brain death protocol Exclusion Criteria: * Pregnant women, patients with advanced renal failure on hemodialysis, with hepatic insufficiency or allergy known to liraglutide

03Change log

Registry changes

No changes recorded since the trial was added.